1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

11 Jun 2024
Admin
News Article

Akums Launches Rabeprazole+Levosulpiride SR Capsules in India

Akums launches rabeprazole+levosulpiride SR capsules in India pioneering relief for GERD patients

Overview

Akums Drugs & Pharmaceuticals Ltd., one of the country’s largest India-CDMO serving the Indian domestic pharmaceutical industry, has announced the launch of Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), this marks the first time such a formulation has been made available in India, promising relief for patients suffering from gastrointestinal tract (GIT) disorders.

GERD

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications.
With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

Rabeprazole Sodium

Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells.
It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD.
Complementing rabeprazole, levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects.
Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology.

Words from Akums Drugs & Pharmaceuticals Ltd

Speaking about the launch, Sanjeev Jain, joint managing director, Akums Drugs & Pharmaceuticals Ltd., commented, “We are thrilled to introduce a novel solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies.”
“Our rabeprazole + levosulpiride SR capsules offer an effective remedy, easing symptoms, enhancing gastrointestinal function, and boosting patients' overall well-being. Clinical studies have demonstrated that rabeprazole not only alleviates heartburn but also improves other dyspepsia-related symptoms. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience.”
Jain added, “The first step to curing any ailment is awareness. It's crucial to raise awareness about GERD to mitigate the risk of developing this condition. The introduction of rabeprazole + levosulpiride SR capsules shows Akums' commitment to effective top-notch pharmaceutical solutions that cater to unmet medical needs. We are optimistic that this novel formulation will make a meaningful difference in the lives of patients. I must appreciate the efforts of our R&D team that has helped in bringing this formulation.

Hard Gelatin Capsule: Content

Each hard gelatin capsule contains rabeprazole sodium IP 40 mg (as enteric-coated form) and levosulpiride 75 mg (as uncoated sustained-release form).
The recommended dosage is one capsule once daily or as directed by a physician.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!